Investing.com - Financial Markets Worldwide
🥇 First rule of investing? Know when to save! Up to 55% off InvestingPro before BLACK FRIDAYCLAIM SALE

Johnson & Johnson's Invokana lowers risk of CV death or hospitalization in T2D

Published 03/12/2018, 12:38 PM
© Reuters. Johnson & Johnson's Invokana lowers risk of CV death or hospitalization in T2D
JNJ
-
  • A new analysis from the CANVAS study showed patients with type 2 diabetes (T2D) treated with Johnson & Johnson (JNJ -0.6%) unit Janssen Pharmaceuticals' INVOKANA (canagliflozin) experienced significantly less risk of cardiovascular (CV) death or hospitalization for heart failure (HHF). The data were presented at the American College of Cardiology Annual Scientific Session & Expo in Orlando, FL.
  • Treatment with INVOKANA reduced the risk of CV death or HHF by 22%, fatal or hospitalized heart failure by 30% and HHF alone by 33%. In patients with prior history of heart failure, the risk of CV death or HHF was reduced 39%. The risk reduction in patients without previous heart failure was 13%.
  • The company's U.S. marketing application seeking approval for a MACE (major cardiovascular events) reduction claim is currently under FDA review.
  • Now read: Johnson & Johnson: The Iconic Health Care Brand Is Attractive


Original article

Latest comments

Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.